Molly brings five years of experience in business development, client relations, and clinical research solutions within the pharmaceutical and MedTech industries. Since joining Symbio in 2024, she has been instrumental in increasing client engagement, fostering strategic partnerships, and maintaining strong relationships with industry partners. Her expertise spans business development, investment firm relations (VC/PE), and clinical research across a variety of therapeutic areas. Molly’s strategic mindset and industry knowledge make her a valuable asset in expanding Symbio’s client partnerships and business growth.
Molly holds a B.S. in kinesiology and an MBA from the University of Rhode Island. She is also Six Sigma certified, enhancing her ability to drive efficiency and process improvement.